Jazz Pharma's sleep disorder drug gets European panel backing

REUTERS: Jazz Pharmaceuticals Plc's treatment for a form of sleep disorder has been recommended for approval in Europe by a panel of the European Medicines Agency , the regulator said on Friday.

Solriamfetol, which will be branded as Sunosi, has been backed for the treatment of excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea , the EMA's human medicines committee said https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019.

OSA is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start, while narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden bouts of sleep. While final approvals are done by the European Commission, it generally follows the panel's recommendation and announces its decision within a couple of months.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

States where recreational marijuana legalized see increased problematic use(Reuters Health) - In the four states where recreational marijuana was legal by 2016, there was a small uptick in cannabis use disorder among ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »